Panatus forte syrup 7,5mg / 5ml fl. 200 ml N1

Dosage form

Transparent liquid from colorless to light yellow with a characteristic lemon odor.

Structure

for 5 ml of syrup

Active ingredient: Butamirate citrate 7.50 mg

Excipients: citric acid, monohydrate 12.50 mg, sorbitol, liquid 1750.00 mg, glycerol 1250.00 mg, sodium saccharin 6.25 mg, sodium benzoate 5.00 mg, lemon flavor 10.00 mg, sodium hydroxide 2 , 50 mg, water purified to 5.00 ml

pharmachologic effect

Butamirate, the active ingredient of Panatus forte, is a centrally acting antitussive agent that does not belong to opium alkaloids either chemically or pharmacologically.

Suppresses cough, having a direct effect on the cough center.

It has a bronchodilating effect.

Helps to facilitate breathing, improving spirometry (reduces airway resistance) and blood oxygenation.

Pharmacokinetics

Butamirate is rapidly and completely absorbed when taken orally.

After taking 150 mg of butamirate, the maximum plasma concentration of the main metabolite (2-phenylbutyric acid) is reached in about 1.5 hours and is 6.4 μg / ml.

With repeated use of butamirate, its concentration in blood plasma remains linear and no cumulation is observed.

Hydrolysis of butamirate, initially to 2-phenylbutyric acid and diethylaminoethoxyethanol, begins in the blood.

These metabolites also have antitussive activity.

Butamirate and its metabolites have an almost maximum (about 95%) degree of binding to blood plasma proteins, which determines their long half-life (T1 / 2) and long-term antitussive effect.

Metabolites are excreted mainly by the kidneys, and acidic metabolites are largely associated with glucuronic acid.

T1 / 2 is 6 hours.

Side effects

From the side of the central nervous system (CNS):

rarely: drowsiness, dizziness.

From the digestive system:

rarely: nausea, vomiting, diarrhea.

From the side of the skin:

rarely: exanthema.

Others: development of allergic reactions is possible.

Selling features

Available without a prescription

Special conditions

The syrup contains sodium saccharin and sorbitol as sweeteners, therefore it can be used in patients with diabetes.

5 ml of syrup (1 scoop) contains 1.75 g of sorbitol.

At each single dose of the drug, the patient receives either 5.25 g of sorbitol (3 scoops), or 3.5 g of sorbitol (2 scoops), or 1.75 mg of sorbitol (1 scoop).

Panatus forte is not used in patients with fructose intolerance.

If after 5-7 days of using Panatus forte the cough does not stop, you should consult a doctor.

Impact on the ability to perform potentially hazardous activities that require special attention and quick reactions (for example, driving vehicles, working with moving machinery)

Panatus forte drug can cause drowsiness, therefore, care must be taken when driving vehicles and working with complex technical devices that require increased concentration of attention and speed of psychomotor reactions.

Indications

Dry cough of any etiology, including whooping cough, to suppress cough in the preoperative and postoperative period, during surgery and bronchoscopy.

Contraindications

Hypersensitivity to the components of the drug, pregnancy (I trimester), breastfeeding, children under 3 years of age, fructose intolerance.

Carefully

Pregnancy (II-III trimesters).

Application during pregnancy and during breastfeeding

There is no data on the safety of using Panatus forte during pregnancy and its passage through the placental barrier.

The drug is not recommended for use in the first trimester of pregnancy.

In the II and III trimesters of pregnancy

Name ENG

PANATUS FORTE

Clinical and pharmacological group

Antitussive drug

ATX code

Butamirate

Dosage

7.5mg / 5ml x 200ml

Structure

5 ml of syrup.

Active ingredient: Butamirate citrate 7.50 mg.

Excipients: citric acid, monohydrate 12.50 mg, sorbitol, liquid 1750.00 mg, glycerol 1250.00 mg, sodium saccharin 6.25 mg, sodium benzoate 5.00 mg, lemon flavor 10.00 mg, sodium hydroxide 2 , 50 mg, water purified to 5.00 ml

Indications

Dry cough of any etiology, including whooping cough, to suppress cough in the preoperative and postoperative period, during surgery and bronchoscopy.

Contraindications

Hypersensitivity to the components of the drug, pregnancy (I trimester), breastfeeding, children under 3 years of age, fructose intolerance.

INN / Active ingredient

butamirate citrate

Storage conditions and periods

At a temperature not exceeding 25 degrees, in the original packaging.

Expiration date: 4 years

Specifications

Category

Cough

Scope of the drug

Ear, Throat, Nose

Release form

Syrup

Manufacturer country

Slovenia

Package quantity, pcs

one

Minimum age from

3 years old

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

KRKA

Components

measuring spoon

The amount of the dosage form in the primary package

200 ml

Primary packaging type

Bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Central antitussive agent

Anatomical and therapeutic characteristics

R05DB13 Butamirate

Dosage form

Syrup

The target audience

Children

Dosage (volume) of the substance in the preparation

7.50 mg

Expiration date in days

1460

Package weight, g

385

Mode of application

:

Inside, before meals.

< br> Children from 3 to 6 years old: 5 ml 3 times a day

children from 6 to 12 years old: 10 ml 3 times a day

children over 12 years old: 15 ml 3 times a day

adults: 15 ml 4 times a day.

< br> Use the measuring spoon (supplied).

1 scoop = 5 ml.

< br> If the cough persists for more than 5-7 days, you should consult a doctor.

Information on technical characteristics, delivery set, country of manufacture